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Abstract
Background: Incidence of Entamoeba histolytica infection and clinical manifestations and treatment response of invasive
amebiasis (IA) in HIV-infected patients have rarely been investigated before.
Methodology/Principal Findings: At the National Taiwan University Hospital, medical records of HIV-infected patients who
received a diagnosis of IA between 1994 and 2005 were reviewed. The incidence of amebiasis was investigated in serial
blood and stool samples from 670 and 264 HIV-infected patients, respectively, using serological and specific amebic antigen
assays. DNA extracted from stool samples containing E. histolytica were analyzed by PCR, sequenced, and compared. Sixty-
four (5.8%) of 1,109 HIV-infected patients had 67 episodes of IA, and 89.1% of them were men having sex with men (MSM).
The CD4 count at diagnosis of IA was significantly higher than that of the whole cohort (215 cells/mL vs. 96 cells/mL). Forty
episodes (59.7%) were liver abscesses, 52 (77.6%) colitis, and 25 (37.3%) both liver abscesses and colitis. Fever resolved after
3.5 days of metronidazole therapy (range, 1–11 days). None of the patients died. The incidence of E. histolytica infection in
MSM was higher than that in other risk groups assessed by serological assays (1.99 per 100 person-years [PY] vs. 0 per 100
PY; p,0.0001) and amebic antigen assays (3.16 per 100 PY vs. 0.68 per 100 PY; p=0.12). In multiple logistic regression
analysis, only MSM was significantly associated with acquisition of E. histolytica infection (adjusted odds ratio, 14.809;
p=0.01). Clustering of E. histolytica isolates by sequencing analyses from geographically-unrelated patients suggested
person-to-person transmission.
Conclusions/Significance: HIV-infected MSM were at significantly higher risk of amebiasis than patients from other risk
groups. Despite immunosuppression, amebic liver abscesses and colitis responded favorably to treatment.
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Introduction
Invasive amebiasis (IA) is the second most common cause of
mortality due to parasite infections worldwide, accounting for
40,000 to 100,000 deaths annually. High risk populations for
developing IA include infants, pregnant women, and patients who
are taking immunosuppressives [1,2]. Interestingly, IA has not
been considered to occur at a higher frequency in HIV-infected
patients [3,4]. In industrialized countries, the rare occurrence of
IA in HIV-infected patients or persons at risk for HIV infection is
probably attributed to the rare intestinal carriage of E. histolytica
[4–9]. This is in contrast with the relatively frequent carriage of
the non-pathogenic E. dispar among men who have sex with men
(MSM) who attend sexually transmitted diseases clinics [10–13]. In
a retrospective review of medical records of more than 34,000
HIV-infected patients in the US [9], 111 (0.3%) patients were
diagnosed as having E. histoytica or E. dispar infection, and only 2
had extra-intestinal amebiasis. Amebiasis was significantly more
prevalent among MSM and patients from E. histolytica endemic
areas. However, the interpretation of the results of this study is
limited by the retrospective study design and failure to differentiate
between E. histolytica and E. dispar [14].
In developing countries, studies comparing the prevalence of
amebiasis in HIV-infected and HIV-uninfected persons yielded
inconsistent results [15–22]. The interpretation of these studies,
however, is difficult because a majority of the diagnosis of
amebiasis was based solely on microscopic examination of stool
samples, which is an insensitive test that fails to distinguish E.
histolytica from E. dispar [14]. In a cross-sectional study using stool
antigen detection and polymerase chain reaction (PCR) from
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HIV-infected patients appeared to have a higher rate, though not
statistically significant, of E. histolytica infection than their sexual
partners or close contacts [23]. However, those patients colonized
with E. histolytica did not develop invasive diseases over the 12-
month follow-up period.
Over the past few years, we and many investigators in Japan,
Taiwan, and Korea have found that IA is increasingly diagnosed
among HIV-infected MSM [24–31]. Of the estimated 500 to 600
reported cases of amebiasis annually in Japan, 80% of them
occurred in MSM [32] and a substantial proportion of patients
with IA were also co-infected with HIV and syphilis [24,30]. In
Taiwan, an estimated 5–6% of HIV-infected patients developed
IA, and in many IA was the presenting disease of HIV infection
[31]. Serologic surveys in the US, Italy, Japan, and Taiwan also
demonstrated that MSM, regardless of HIV status, were at an
increased risk of exposure to E. histolytica [13,26,31,33–35]. Recent
detection of locally acquired amebiasis among MSM who had no
recent travel to endemic areas for E. histolytica has raised concerns
in Sydney, Australia [36]. Oral-anal sexual contact has been found
to be significantly associated with acquisition of E. histolytica
infection [37]. Although IA has been considered an increasingly
important parasitic infection in HIV-infected patients in three East
Asian countries, the incidence of amebiasis and the clinical
spectrum and the response of IA to standard metronidazole
therapy have not been well studied.
Inthisstudy,weconductedalongitudinalfollow-upstudyto assess
the incidence of E. histolytica infection among persons with HIV
infection at a referral medical center for HIV care in Taiwan. We
also described the clinical spectrum and treatment outcome of IA.
Methods
Retrospective review of invasive amebiasis cases
Medical records of 1109 consecutive, non-hemophiliac HIV-
infected patients aged 15 years or greater were reviewed to identify
cases of IA at the National Taiwan University Hospital from June
1994 to December 2005 with the use of a standardized case record
form. Of the 1109 patients, 781 (70.4%) were MSM. During the
study period, a standardized protocol was followed to investigate
HIV-infected patients who presented with gastrointestinal symp-
toms [28,31]. Those investigations included at least two stool
specimens for bacterial cultures and microscopy of concentrated
wet mount preparations and modified acid-fast staining; indirect
hemagglutination (IHA) assay to detect anti-E. histolytica antibodies
(Cellognostics, Boehhringer Diagnostics GmbH, Marburg, Ger-
many); endoscopy and biopsy for histopathologic examinations in
patients whose stool examinations were non-diagnostic; abdominal
sonography followed by computed tomography for patients with
abnormal liver function tests, and space-occupying lesions of the
liver. Specific Entamoeba antigen assays using commercial test kits
(ENTAMOEBA TEST, TechLab, Branchburg, NJ) followed by
polymerase chain reactions (PCR) using specific primers for E.
histolytica was introduced after 1 January, 2001 [31].
Definite IA was diagnosed when erythrophagocytic trophozoites
and/or positive PCR to E. histolytica were identified in clinical
specimens from patients with symptoms compatible with IA, such
as colitis and liver abscesses [28,38]. Probable IA was confirmed
when a patient with IA symptoms responded to metronidazole
monotherapy and the aspirates or blood specimens showed high
IHA titers, but microbiological cultures for bacteria, fungi, or
histopathological examination of aspirates and biopsy specimens
did not reveal any other pathogen. Results of the IHA assay were
considered positive if the titer was 128 or greater. AIDS was
defined according to the 1993 revised classification system for HIV
infection and expanded surveillance case definition for AIDS
among adolescents and adults [39]. Highly active anti-retroviral
therapy (HAART) was defined as anti-retroviral therapy contain-
ing two nucleoside reverse transcriptase inhibitors and a (boosted)
protease inhibitor(s) or a non-nucleoside reverse transcriptase
inhibitor.
Sero-incidence of E. histolytica infection
Serum samples from HIV-infected patients at baseline were
tested for IHA and patients who remained in clinic follow-up from
January 2001 to December 2005 were re-tested to determine the
sero-incidence of E. histolytica infection. The interval between the
two blood samples was at least one year. In patients with samples
that tested positive at the last clinic follow-up or the end date of the
study (31 December, 2006), serially stored serum samples were
retrospectively tested to determine the seroconversion date.
Seroconversion was defined as changes from sero-negative at
baseline to IHA titers of 128 or greater at subsequent IHA assay;
or increases of IHA titers by four-fold or greater. The
seroconversion date was defined as the mid-point between the
dates when the last sero-negative sample and the first sero-positive
sample were collected.
Incidence of intestinal infection with E. histolytica
Sequential stool samples from HIV-infected persons were tested
for the presence of stool Entamoeba antigen between 1 January,
2001 and 31 December, 2005. Those patients who were negative
for Entamoeba antigen were asked to provide stool samples for
follow-up testing using the same method in order to assess the
incidence of new acquisition of E. histolytica.The interval between
the two stool samples were at least 6 months. The date of new
infection was estimated as the mid-point between the date when
the last antigen-negative sample and the first antigen-positive
sample were collected.
Stool specimens tested positive for E. histolytica/E. dispar antigen
were further confirmed by PCR. The primer sets for a multiplex
nested PCR were based upon the variable regions between 16S-
like rDNAs of E. histolytica (GenBank X56991) and E. dispar
(GenBank Z49256) [31]. The procedures to isolate total DNA
Author Summary
Entamoeba histolytica, morphologically identical to but
genetically different from E. dispar and E. moshkovskii,i s
the causative agent of amebiasis. Recently there have been
reports of increased risk for amebiasis among men who
have sex with men (MSM) due to oral-anal sexual contact
in several developed countries. In this longitudinal follow-
up study, the incidence of amebiasis was determined
among HIV-infected patients using serological and specific
amebic antigen assays. DNA extracted from stool samples
containing E. histolytica were analyzed by PCR, sequenced,
and compared. Clinical manifestations and treatment
response of invasive amebiasis in HIV-infected patients
were reviewed. The results demonstrated that HIV-infected
MSM were at significantly higher risk of amebiasis than
patients from other risk groups. Clustering of E. histolytica
isolates by sequencing analyses from geographically
unrelated patients suggested person-to-person transmis-
sion. Despite immunosuppression, amebic liver abscesses
and colitis responded favorably to metronidazole therapy.
It is important to investigate in areas of high incidence of
both amebiasis and HIV (sub-Saharan Africa) how gener-
alizable these findings are.
Amebiasis and HIV Infection
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previously [31]. Individual E. histolytica isolates were genotyped by
PCR amplification and sequencing of the previously described
polymorphic loci, locus 1-2, using one set of primers (R1:
CTGGTTAGTATCTTCGCCTGT and R2: CTTACACCCC-
CATTAACAAT) previously described [40,41]. PCR was carried
out in a 50 ml reaction mixture containing 0.1 mg of DNA, a
1.5 mM concentration of each primer, 2.5 mM MgCl2, a 100 mM
concentration of each deoxynucleoside triphosphate, and 1.5 U of
AmpliTaq Gold DNA Polymerase (Applied Biosystems) with the
Taq activation at 95uC for 15 min and 30 cycles of denaturation at
94uC for 30 s, annealing at 45uC for 30 s, and extension at 72uC
for 1 min, and then final extension at 72uC for 10 min [40]. The
PCR products were fractionated by electrophoresis in 3% NuSieve
3:1 agarose (Cambrex, East Rutherford, USA), stained by
ethidium bromide and visualized under UV illumination. After
purification using the QIAquick PCR purification kit (QIAGEN),
locus 1-2 PCR products were sequenced twice in the forward and
reverse directions. The sequences from representative genotypes
chosen to infer the phylogenetic trees of locus 1-2 were were
manually edited and aligned by using BioNumerics V. 4.01
software (Applied Maths, Kortrijk, Belgium). The study protocols
were approved by the Institutional Review Board of NTUH and
patients gave written informed consent.
Statistical analysis
All statistical analyses were performed using SAS statistical
software (Version 8.1, SAS Institute Inc., Cary, NC, U.S.A.).
Categorical variables were compared using x
2 or Fisher’s exact test
and non-categorical variables were compared using Wilcoxon’s
rank-sum test. The incidence rate of E. histolytica infection or
seroconversion was calculated as number of episode per 100 person-
years (PY) of observation. Exact 95% confidence intervals (95% CI)
for incidence rates were calculated on the basis of the Poisson
distribution. The follow-up duration was from the date with the first
stool or blood sample that was negative for E. histolytcia antigen or
IHA to the date with the sample that was positive, date of death, or
on 31 December, 2006, whichever occurred first. Multiple logistic
regression analysis was performed between patients who were
diagnosed with newly acquired E. histolytica infection by serologies or
antigen assays and those who remained uninfected in order to
identify the risk factors associated with E. histolytica infection. All tests
were two-tailed. A p value ,0.05 was considered significant.
Results
Cases of invasive amebiasis
During the 11-year study period, 64 (5.8%) HIV-infected
patients were diagnosed as having 67 cases of IA (Table 1). All of
the 64 patients were males and 57 (89.1%) were MSM. MSM had
a higher risk of invasive amebiasis compared with other risk
groups: 57/781 vs. 7/328 (risk ratio, 3.42; 95% CI, 1.5777, 7.417).
In 29 cases (43.8%), HIV infection was concurrently diagnosed
with IA. The CD4 count at diagnosis of IA was significantly higher
than that of the whole cohort (215 cells?L vs. 96 cells?L). Fever
(72.6%), diarrhea (70.8%), right upper quadrant pain (32.3%), and
dysentery (20.6%) were the most common symptoms of IA. Fifty-
two (77.6%) of the 67 IA episodes were amebic colitis, 40 (59.7%)
episodes were liver abscesses (including 4 multiple abscesses), and
25 (37.3%) were both amebic liver abscesses and colitis (Figures 1
and 2). By IHA assays, 51.6% of the patients with IA had
titers§512 (range, 0–16384). Eight (11.9%) developed serious
complications necessitating surgical intervention, which included 3
intestinal perforations and peritonitis, 2 ruptures of the liver
abscess, 2 subphrenic abscesses, 1 empyema, and 1 hepatogastric
Table 1. Clinical characteristics of 64 patients with 67
episodes of invasive amebiasis.
Variable (No. of data available)
N (%) or Median
(range)
Route of HIV transmission (67)
Homosexual/bisexual 57 (85.1)
Heterosexual 10 (14.9)
Age at diagnosis (65) 34.0 (21–72)
CD4 at diagnosis (56) 198.0 (1–294)
PVL at diagnosis (log10 copies/ml)* (40) 5.0 (1.7–6.1)
HAART use at diagnosis* (65) 11 (16.9)
Clinical presentation
Fever (63) 45 (71.4)
Diarrhea (65) 46 (70.8)
Watery stool (62) 31 (50)
Dysentery (63) 13 (20.6)
Abdominal pain (63) 39 (61.9)
Right upper quadrant pain (63) 20 (31.7)
Cough (63) 8 (12.7)
Laboratory
White blood cell count (/l) (53) 8740.0 (2110–38140)
Hemoglobin (g/dL) (53) 11.3 (4.7–16.2)
GOT (IU/L) (52) 38.0 (11.0–1090.0)
GPT (IU/L) (47) 28.0 (5.0–856.0)
ALP (IU/L) (46) 190.5 (25.0–722.0)
Total bilirubin (mg/dL) (49) 0.51 (0.1–2.1)
Stool exam positive for E. histolytica/E. dispar (51) 10 (19.6)
Stool E. histolytica/E. dispar Ag (28) 7 (25.0)
Stool PCR positive for E. histolytica (27) 3 (11.1)
Colonoscopy showing colon ulcers (23) 6 (26.1)
Abdominal sonography (55)
Right lobe abscess 26 (51.0)
Left lobe abscess 9 (17.6)
Disease involvement
Liver abscess (40)
Definite 5 (12.5)
Probable 35 (87.5)
Colitis (52)
Definite 20 (38.5)
Probable 32 (61.5)
Treatment
Metronidazole (61) 60 (98.4)
Metronidazole monotherapy (56) 21 (37.5)
Time to persistently afebrile, days 3 (1–6)
Concurrent other antibiotic use .3 days (56) 35 (62.5)
Time to persistently afebrile, days 2 (0–10)
Receipt of iodoquinol (60) 42 (70.0)
Operation and/or drainage (63) 14 (22.2)
Duration of follow-up (d) (57) 623.5 (10–3888)
Ag: antigen; ALP: alkaline phosphatase; GOT: aminotransferase; GPT:
aminotransferase; HAART: highly active antiretroviral therapy; PCR: polymerase
chain reaction; PVL: plasma HIV RNA load.
*At diagnosis of invasive amebiasis.
doi:10.1371/journal.pntd.0000175.t001
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days) and the interval from initiation of metronidazole to
defervescence was 3.5 days (range, 1–11 days). Thirty-five patients
received concurrent antibiotic therapy, mainly ceftriaxone, and
the fever resolved after 2 days of antibiotic therapy (range, 0–10
days). Of 21 patients receiving only metronidazole, the fever
resolved after 3 days of therapy (range, 1–6 days). Liver aspiration
and drainage was performed in 14 (20.9%) patients. Two required
a laparotomy and chest tube drainage. Iodoquinol was adminis-
tered to 42 (62.7%) patients following completion of metronidazole
therapy to clear intestinal colonization and prevent relapse.
Nobody died of IA after a median observation of 748 days (range,
9–4179 days).
Sero-incidence of E. histolytica infection
Of 991 patients (89.4%) with available IHA assay results at
baseline, 66 patients (6.7%) had IHA titers of 128 or greater.
Between January 2001 and December 2005, 670 patients,
including 433 (63.6%) MSM, who had more than one blood
sample available for follow-up IHA assay, were enrolled in the
sero-incidence study (Figure 3). There were no significant
differences in demographics and clinical characteristics between
the 670 patients who had follow-up IHA assays and the 321 who
did not (data not shown). There were no significant differences in
median CD4 count and plasma HIV RNA load (PVL) between
MSM and patients from other risk groups when the first IHA
assays were performed. At baseline, a significantly higher
proportion of MSM (7.2%) had IHA titers of 128 or greater than
patients from other risk groups (p=0.006) (Table 2).
The median interval between the two blood samples was 1054
days (interquartile range [IQR], 606–1857 days) (Table 2).
Twenty-one (3.1%) of the 670 HIV-infected patients seroconvert-
ed with IHA titers from 0 to 128 or greater; the median interval for
seroconvertion was 1507 days (IQR, 790–2039 days). MSM were
at statistically significantly higher risk for seroconversion for E.
histolytica infection. The crude sero-incidence of E. histolytica
infection among MSM was 4.9% compared with 0% among
other risk groups (p,0.0001). The incidence rate of seroconversion
was 1.44 per 100 PY (95% CI, 0.89, 2.20 per 100 PY) among
MSM, compared with 0 per 100 PY (95% CI, 0, 0.38 per 100 PY)
among patients of other risk groups (p,0.0001). When an increase
of IHA titer by 4-fold or greater was included along with changes
of IHA titers from 0 to 128 or greater, the incidence rate of
seroconversion was 1.99 per 100 PY (95% CI, 1.33, 2.86 per 100
PY) among MSM, compared with 0 (95% CI, 0, 0.38 per 100 PY)
among patients of other risk groups (rate ratio, 19.15; 95% CI,
2.61, 140.6) (p,0.0001).
Longitudinal survey of intestinal colonization with E.
histolytica
Four hundred and sixty-nine (37.6%) patients, including 303
(64.6%) MSM, provided a total of 732 stool samples (range, 2–6
samples; median, 3 samples) for antigen testing between 2001 and
2005. At baseline, 45 (9.6%) patients, including 36 MSM (80%),
had stool samples that tested positive for E. histolytica/E. dispar
antigen. Two hundred and sixty-four patients, including 165
(62.5%) MSM, who had no intestinal infection with E. histolytica/E.
dispar at baseline by specific stool antigen assays submitted more
than one stool sample for repeat antigen assays (Table 3). At the
Figure 1. Abdominal computed tomography showing multiple
liver abscesses of a 28-year-old male homosexual who
presented with right upper quadrant pain, vomiting, and
watery diarrhea for 4 days. Diagnosis of amebic liver abscess was
confirmed by positive PCR for Entamoeba histolytica of the liver abscess
aspirate. The titer of indirect hemagglutination antibody for E.
histolytica was 8192.
doi:10.1371/journal.pntd.0000175.g001
Figure 2. Colonoscopy of the same patient showing multiple ulcers at the cecum, and ascending, transverse, and descending colon.
doi:10.1371/journal.pntd.0000175.g002
Amebiasis and HIV Infection
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(8.5%) had IHA titers of 128 or greater than patients from other
risk groups (2.0%) (p=0.03).
After an observation period of 399 PY, 19 (7.2%) patients were
found to be infected with E. histolytica/E. dispar; 9 (47.4%) of the 19
isolates were E. histolytica by PCR. The median interval between the
negative and positive antigen tests of the 19 patients was 287 days
(IQR, 221–393 days). The crude incidence of new E. histolytica/E.
disparinfection amongMSM was8.5%,comparedwith5.1%among
patients from other risk groups (p=0.37); the incidence rate of new
acquisition of E. histolytica/E. dispar infection was 5.56 per 100 PY
(95% CI, 3.04, 9..32 per 100 PY) among MSM, compared with 3.40
per 100 PY (95% CI, 1.10, 7.94 per 100 PY) among patients from
other risk groups (p=0.36). Of the 9 E. histolytica isolates, 8 isolates
were from 165 MSM, while 1 was from 99 patients from other risk
groups (p=0.16). The incidence rate of E. histolytica infection was
3.16 per 100 PY (95% CI, 1.37, 6.23 per 100 PY) among MSM
compared with 0.68 per 100 PY (95% CI, 0.02, 3.79 per 100 PY)
among patients from other risk groups with a rate ratio of 4.667
(95% CI, 0.5837, 37.31) (p=0.12). All of the patients with E.
histolytica infection were asymptomatic.
Six of 9 (66.7%) patients, who acquired new E. histolytica
infection, seroconverted from sero-negative to sero-positive for
anti-E. histolytica antibodies, compared with only 2 of 255 (0.78%)
who did not acquire E. histolytica infection (odds ratio, 251 [95%
CI, 35.22, 1789]) (p,0.0001).
The results from sequencing extracted DNA from the E.
histolytica isolates in this study and other isolates of E. histolytica from
our previous prevalence study [31] are shown in Figure 4. Case
clustering among isolates from MSM was noted (Locus1-2 allelic
genotypes B and D), suggesting a common source or person-to-
person transmission. However, geographical unrelatedness among
those patients with intestinal E. histolytca infection suggests that
person-to-person transmission of E. histolytica might have occurred
among MSM.
In univariate analysis, patients acquiring amebiasis were
predominantly MSM and had significantly higher CD4 counts
than those who remained uninfected (315 vs. 157 cells/L;
Figure 3. Study populations to determine the incidence of amebiasis among HIV-infected patients between 1994 and 2005.
doi:10.1371/journal.pntd.0000175.g003
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we found that MSM was the only risk factor that was associated
with new acquisition of E. histolytica infection by serologies or
antigen assays followed by PCR, with an adjusted odds ratio of
14.809 (95% CI, 1.824, 120.237; p=0.01) when compared with
heterosexuals or patients with other risk behaviors (data not
shown). The adjusted odds ratio for new acquisition of E. histolytica
infection for every 50-cells/L CD4 increase or 12log10 copies/ml
plasma HIV RNA load decrease was 1.066 (95% CI, 0.975, 1.167;
p=0.16) and 1.180 (95% CI, 0.813, 1.713; p=0.38), respectively.
Discussion
This is the first longitudinal follow-up study to investigate the
incidence of E histolytica infection in HIV-infected patients by
examining the incidence rate of intestinal E. histolytica infection and
seroconversion of anti-E. histolytica antibodies. We found that HIV-
infected MSM were at significantly higher risk for acquisition of E.
histolytica infection [31,34]. Despite immunosuppression from HIV
infection and the complicated disease course of IA, clinical
responses to metronidazole therapy were favorable in terms of
rapid defervescence and a low attributable mortality rate.
Exposure to E. histolytica, but not E. dispar, may induce anti-E.
histolytica antibody response and development of anti-E. histolytica
antibodies may represent either recent or remote exposure to E.
histolyica [14,42], although not every person infected with E. histolytica
develops an antibody response. Our analysis also showed that
acquisition of E. histolytica infection was significantly associated with
seroconversion for anti-E. histolytica antibodies despite immunosup-
pression from HIV infection. Therefore, such a test may be used as a
complimentary tool to understand the epidemiology of E. histolytica
among high-risk populations. By using serological surveys, Japanese
investigators have found that the seroprevalence of E. histolytica
infection in MSM was as high as 13.4–20.4% compared with 1.0%
in heterosexuals and 0.8% in prostitutes [24–26,33]. Similarly, we
found that the seroprevalence of E. histolytica infection among HIV-
infected patients remained significantly higher compared with HIV-
uninfected persons with gastrointestinal symptoms who had their
sera tested for anti-E. histolytica antibodies [34].
In this study, we further explored the sero-incidence of E.
histolytica infection in HIV-infected patients. The results also
indicate that MSM are at increased risk of exposure to E. histolytica
infection. The findings of higher seroprevalence and sero-
incidence of MSM, regardless of HIV status, are caused by higher
prevalence and incidence of intestinal infection with E. histolytica.
In our previous study, we found that the prevalence of E.
histolytica/E. dispar by stool antigen tests was 12.1%, compared with
1.4% healthy controls; and at least 25% of the isolates from HIV-
infected persons were confirmed as E. histolytica by PCR [31].
Although the majority of persons infected with E. histolytica are
asymptomatic [1,2], more than 80% of the 600 or greater annually
reported cases of amebiasis in Japan occurred in MSM [32]. These
findings may reflect a decrease in E. histolytica infection in
developed countries where improvement of public hygiene and
sanitation has reduced the risk of acquisition of E. histolytica
through contaminated water or food.
Sharing the identical transmission route with E. histolytica, the
transmission of E. dispar among MSM in developed countries is
Table 2. Characteristics of non-hemophiliac patients aged 15 years or greater who had baseline and follow-up indirect
hemagglutination (IHA) assays.
Variable MSM Heterosexuals and Other All Statistics, p=
Patients, N 433 237 670
Sex, M/F 433/0 184/53 617/53 ,0.0001
Age when first IHA was determined, median (IQR), y 32 (27, 38) 40 (32.5, 51) 35 (29, 42) ,0.0001
Age when second IHA was determined, median (IQR), y 36 (31, 42) 44 (38, 55) 39 (33, 46) ,0.0001
CD4 when first IHA was determined, median (IQR), cells/L 183 (45, 413) 135 (24, 323) 173 (37, 389) 0.02
CD4,200 cells/L, N (%) 195 (51.7) 102 (56.4) 297 (53.2) 0.30
CD4 when second IHA was determined, median (IQR), cells/L 400.5 (258, 593) 353 (223, 541) 385.5 (247.5, 574.5) 0.069
CD4,200 cells/L (%) 74 (18.4) 48 (21.6) 122 (19.6) 0.33
Interval between two IHA tests, median (IQR), days 958 (592,1700) 1184 (660, 2108) 1054 (606,1857) 0.002
HAART initiated, N (%) 401 (92.6) 228 (96.2) 629 (93.9) 0.07
Geometric mean IHA titer at baseline 134.19 48.11 100.83 0.16
IHA§128, N (%) 31 (7.2) 5 (2.1) 36 (5.4) 0.006
Geometric mean IHA titer of the second test 108.89 33.90 89.64 0.0002
IHA§128, N (%) 46 (10.6) 3 (1.3) 49 (7.3) ,0.0001
Total observation duration, PY 1458 963 2421
*Seroconversion, N (%) 21 (4.9) 0 (0) 21 (3.1) ,0.0001
Incidence rate, per 100 PY (95% CI) 1.44 (0.89, 2.20) 0 (0, 0.38) 0.87 (0.54, 1.33) ,0.0001
**Seroconversion, N (%) 24 (5.5) 0 (0) 24 (3.6) ,0.0001
Incidence rate, per 100 PY (95% CI) 1.65 (1.05, 2.45) 0 (0, 0.38) 0.99 (0.64, 1.47) ,0.0001
Abbreviations: 95% CI, 95% confidence interval; 100 PY, 100 persons-years of observation; IDU: intravenous drug user; IQR, interquartile range; MSM, men who have sex
with men.
Note: *Seroconversion from 0 at baseline to §128 at second tests. Rate ratio (MSM vs. patients of other risk groups): 13.87 (95% CI, 1.866, 103.1).
** Seroconversion from 0 at baseline to §128 at second tests; or from any titer at baseline to 4-fold rise or greater than baseline values. Rate ratio: 19.15 (95% CI, 2.61,
140.6).
doi:10.1371/journal.pntd.0000175.t002
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antigen assays.
Variable MSM Heterosexuals and Other All Statistics, p=
Patient number, N 165 99 264
Sex, M/F 165/0 82/17 247/17 ,0.0001
Age at first stool antigen assay, median (IQR), y 36 (31, 42) 44.5 (35, 52) 38 (32, 46) ,0.0001
Median stool samples submitted from each person, (range) 3 (2, 6) 3 (2, 6) 3 (2, 6) 0.69
CD4 when first stool antigen assay was performed, median (IQR),
cells/L
295.5 (157, 490) 249 (129, 378) 282 (136, 445) 0.06
CD4,200, N (%) 50 (33.3) 38 (42.7) 88 (36.8) 0.17
CD4 at subsequent positive assays or the last negative assays,
median (IQR), cells/L
372 (254, 541) 308 (185, 432) 336 (223, 512) 0.006
CD4,200 cells/L, N (%) 18 (13.0) 26 (31.3) 44 (19.8) 0.002
Interval between the first negative stool antigen and subsequent
positive assays or the last negative assays, median (IQR), days
423 (244, 933) 451 (258, 771) 430.5 (245, 826.5) 0.83
HAART initiated, N (%) 152 (92.1) 98 (99.0) 250 (94.7) 0.02
Geometric mean IHA titers at baseline 322.54 90.51 256 0.045
IHA§128, N (%) 14 (8.48) 2(2.02) 16(6.06) 0.03
Total observation duration, PY 252 147 399
From first antigen-negative at baseline to first antigen-positive
tests, N (%)
14 (8.5) 5 (5.1) 19 (7.2) 0.37
Interval between two tests, median (IQR), d 279.5 (221, 393) 317 (245, 319) 287 (221, 393) 0.93
Incidence rate of E. histolytica/ E. dispar infection, per 100 PY
(95% CI)
5.56 (3.04, 9..32) 3.40 (1.10, 7.94) 4.76 (2.87, 7.43) 0.36
From first antigen-negative at baseline to the first antigen-
positive and PCR-positive tests, N (%)
8 (4.85) 1 (1.01) 9 (3.41) 0.16
Interval between two tests, median (IQR) 459 (311, 747.5) 245 427 (245, 708) 0.44
*Incidence rate of E. histolytica infection, per 100 PY (95% CI) 3.16 (1.37, 6.23) 0.68 (0.02, 3.79) 2.26 (1.03,4.28) 0.12
Abbreviations: 95% CI, 95% confidence interval; 100 PY, 100 persons-years of observation;
IDU: intravenous drug user; IHA: indirect hemagglutination; IQR, interquartile range; MSM, men who have sex with men; PCR, polymerase chain reaction.
Note: *Rate ratio (MSM vs. patients of other risk groups): 4.083 (95% CI, 0.5025, 33.18).
doi:10.1371/journal.pntd.0000175.t003
Figure 4. Results E. histolytica genotyping.
doi:10.1371/journal.pntd.0000175.g004
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who visited the sexually transmitted diseases clinic were found to
be infected with E. dispar [10–12]. Therefore, infection with either
E. dispar or E. histolytica is indicative of unsafe oral-anal sexual
contact among MSM. In this study, we further demonstrated that
HIV-infected MSM were more likely than other risk groups to
acquire E. histolytica infection during follow-up, although this
finding is not statistically significantly different due to the small
sample size. Nearly 4% of HIV-infected MSM acquired E.
histolytica, compared with 1% among patients from other risk
groups. Furthermore, case clustering that was identified by
molecular typing of the isolates occurred probably through
person-to-person transmission. These findings highlight the
importance of counseling MSM about precautions to prevent
acquiring E. histolytica infection through oral-anal sexual contact.
The clinical manifestations of IA in our HIV-infected patients
with significant immunosuppression were similar to those
previously described in HIV seronegative patients. Amebic colitis
and liver abscesses were the two most common presentations
[1,2,29]. The severity of the diseases was reflected by the high
proportion of liver abscesses (59.7%) and complications (11.9%) in
our cases. Despite low CD4 counts upon diagnosis with IA, the
responses to metronidazole therapy with or without combination
with antibiotics were favorable, as shown by rapid defervescence
within 2 days of therapy initiation and no death attributable to IA.
There are several limitations of our study. First, the risk for
exposure to E. histolytica is low in the general population in Taiwan,
as reflected by the low seroprevalence (0.12%) of E. histolytica
infection among 2500 healthy controls in a recent survey in
northern and southern Taiwan [34]. Therefore, generalizations
about our findings to areas of higher endemicity of E. histolytica and
HIV infection should be cautious. Second, most patients at the late
stage of HIV infection who develop HIV-related complications are
referred to this hospital. However, those patients with IA had
significantly higher CD4 counts than the patients without IA,
suggesting that E. histolyica infection may not be associated with
immunosuppression in HIV-infected patients. Rather, it is the
risky behavior that increases risk of E. histolyica infection and
subsequent development of invasive diseases. Third, our study was
limited by the small sample size in assessment of the incidence of
E. histolytica infection by stool antigen assays during follow-up.
Although the incidence of E. histolytica infection is higher in MSM
than in heterosexuals and others, the difference does not reach
statistical significance. The shedding of E. histolytica may be
intermittent, which may reduce the sensitivity of antigen assays if
only one stool sample is tested. However, combinations with IHA
assays for E. histolytica infection in our study may compensate for
this deficiency by increasing the detection sensitivity. In this study,
we chose a high titer of 128 as the cut-off value which decreases
the possibility of cross-reactions, and seroconversion was signifi-
cantly associated with newly acquired E. hisitolytica infection. Last,
our genotyping methods [40,41] may not be as sensitive enough
for detection of genetic differences between the isolates as the new
genotyping system that uses 6 tRNA-linked short tandem repeats
by Ali and colleagues [43].
In conclusion, HIV-infected MSM in Taiwan are at a higher
risk of acquisition of E. histolytica infection and IA than other HIV-
infected patients. It should also be investigated whether this is the
case in other countries. Certainly physicians, treating MSM with
or without HIV infection, should be aware of this potential
complication, that until recently, in industrialized countries was
seen nearly only in travelers returning from E. histolytica endemic
regions.
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